Table 1.

Clinical characteristics of the transplant study groups.

	Short term (prospective)	Long term (retrospective)	p value
Recipient gender	25 M/11 F	27 M/13 F	0.527
Age at KTx	52.9 ± 11.2 y (56; 46.5–62 y)	41.0 ± 13.5 y (42; 27.5–52.5 y)	<0.001
Age during the study	52.9 ± 11.2 y (56; 46.5–62 y)	48.9 ± 13.2 y (52; 37–59)	0.153
Time from KTx to examination	1°: 3–5 days	7.9 ± 2.2 y (7; 6–10 y)	<0.001
	2°: 30–42 days
	3°: 90–123 days
	4°: 195–225 days
	5°: 365–443 days
RRT before tx	24.7 ± 13.6 y (24; 14–33 y)	23.5 ± 17.2 y (19; 12–29 y)	0.398
Donor gender	26 M/10 F	27 M/13 F	0.423
Donor age	45.6 ± 14.2 y (53; 33–56.5 y)	43.5 ± 13.2 y (45; 37–52 y)	0.243
HLA mismatches	From 1 to 6, median 4	From 1 to 5, median 3
Panel-reactive antibodies (PRA)	16 recipients (3–61%)	19 recipients (4–50%)
Cold ischemia time	24.2 ± 6.8 h (24; 20–29 h)	25.4 ± 8.2 h (24; 21–29 h)	0.820
Delayed graft function	5 recipients	6 recipients	0.597
Acute rejection episodes	11	15	0.347
Maintenance IS	Tac/MMF/steroids 20	Tac/MMF/steroids 13
	Tac/Aza/steroids 2	Tac/Aza/steroids 1
	CsA/MMF/steroids 13	CsA/MMF/steroids 11
	CsA/Aza/steroids 1	CsA/Aza/steroids 15
1-year eGFR	51.4 ± 14.1 y (49; 42–60 y)	52.6 ± 16.6 y (51, 40–60 y)	0.844

Abbreviations: IS: immunosuppression; Tac: tacrolimus; MMF: mycophenolate mofetil or sodium; Aza: azathioprine; CsA: cyclosporine A.